(Press-News.org) ORLANDO — A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53.
Michael Andreeff, M.D., Ph.D., professor of Medicine and chief of Molecular Hematology and Therapy in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presented preliminary results of this ongoing Phase I study at the 52nd Annual Meeting of the American Society of Hematology. The clinical trial is under way at MD Anderson and five other sites in the United States and United Kingdom.
The first-in-class drug has shown clinical activity in some patients and been well-tolerated, Andreeff said.
Andreeff has been researching the interaction between MDM2 and p53 for five years. He says he believes this study may lead to an effective new way to fight some types of cancer with fewer side effects.
"P53 can be activated by chemotherapy or radiation, but both of these therapies carry risks of causing secondary tumors," he said. "If we can activate this tumor-suppressor with a method that is non-genotoxic and does not cause damage to a patient's DNA, we may be able to help avoid secondary tumors caused by other treatments."
Too much MDM2 degrades p53
Normally, p53 halts the division of defective cells and forces them to commit suicide or lose the ability to reproduce. However, the tumor suppressor is disabled in many types of cancer, often because of gene mutations or defective signaling.
While mutations of the TP53 gene are rare in cancers of the blood, the p53 protein may be degraded by other factors, including high levels of MDM2, which binds to p53 and orchestrates its degradation.
Previous research has suggested that p53 activation by disrupting the binding of MDM2 to p53 may be a novel strategy for cancer therapy. In preclinical studies, small-molecule MDM2 antagonists called Nutlins were found to be effective in solid tumors, leukemia and lymphoma.
The drug used in this study, RG7112, a novel small molecule being developed by Roche, is a member of the Nutlin family.
Clinical effects seen
Patients with relapsed or refractory acute or chronic leukemia were given RG7112 orally each day for 10 days, followed by 18 days of rest. Forty-seven patients, including 27 with acute myeloid leukemia (AML), have been treated to date.
There has been evidence of clinical activity, and one patient with AML has been leukemia-free for nine months. Reductions in lymph node and spleen size, as well as in circulating leukemia cells, were seen in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
"RG7112 has been well tolerated, and we've seen some effectiveness," Andreeff said. "So far it has done exactly what we thought it would. This gives us evidence it can be used in patients, is well-tolerated and can be given in dosages that can escalate to a point that shows a higher response rate."
Next steps
Enrollment in this study is ongoing and will be updated. Future single-agent and combination studies of RG7112 in leukemias are planned.
###
Co-authors with Andreeff are Kensuke Kojima, M.D., Ph. D., Molecular Hematology & Therapy, MD Anderson Department of Leukemia and Susan O'Brien, M.D., Gautam Borthakur, M.D., and Marina Konopleva, M.D., Ph.D., all of the Department of Leukemia; Felipe Samaniego, M.D. MD Anderson Department of Lymphoma/Myeloma; Swaminathan Padmanabhan, M.D., The University of Texas Health Science Center at San Antonio; Roger Strair, M.D., Cancer Institute of New Jersey, New Brunswick; Mark Kirschbaum, M.D., City of Hope National Medical Center, Duarte, Calif.; Peter Maslak, M.D., Memorial Sloan-Kettering Cancer Center, New York; Peter Hillmen, MBChB, Ph.D., St. James's University Hospital, Leeds, United Kingdom; and Lyubomir Vassilev, Ph.D. and Gwen Nichols, M,D., Roche, Nutley, NJ
The research was funded in part by Roche and by grants from the National Cancer Institute to Andreeff.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010,
MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in
U.S. News & World Report.
Get MD Anderson News Via RSS Follow MD Anderson News on Twitter
END
New Rochelle, NY, December 7, 2010—NASA-funded research has uncovered a new life form on Earth, a microorganism that can not only survive but can thrive and reproduce by metabolizing arsenic, a chemical that is highly toxic for most other earthly organisms. This finding will revolutionize the field of astrobiology—the study of the origins, evolution, distribution, and future of life in the universe. Astrobiology, a peer-reviewed journal from Mary Ann Liebert, Inc.(www.liebertpub.com), has been the defining journal in this exciting area of study for the last decade. Table ...
System 94B has not been classified as a tropical depression, but NASA satellite data has shown that it is creating heavy rainfall near India's southeastern coast. A second NASA satellite revealed that strong wind shear is continuing to push convection to the northwest of System 94B's center of circulation.
The Tropical Rainfall Measuring Mission (TRMM) satellite viewed an area of thunderstorms associated with System 94B near the east coast of India in the Bay of Bengal on December 7 at 0123 UTC. Data from TRMM's Precipitation Radar (PR) and Microwave Imager (TMI) showed ...
GREENBELT, Md. -- A new NASA computer modeling effort has found that additional growth of plants and trees in a world with doubled atmospheric carbon dioxide levels would create a new negative feedback – a cooling effect – in the Earth's climate system that could work to reduce future global warming.
The cooling effect would be -0.3 degrees Celsius (C) (-0.5 Fahrenheit (F)) globally and -0.6 degrees C (-1.1 F) over land, compared to simulations where the feedback was not included, said Lahouari Bounoua, of Goddard Space Flight Center, Greenbelt, Md. Bounoua is lead author ...
CHAMPAIGN, Ill. – The flurry of smart-phone patent suits at the U.S. International Trade Commission (ITC) is being driven by technology companies eager to capitalize on the speed and expertise of the specialized venue, says a University of Illinois patent strategy expert.
Business professor Deepak Somaya says that this current wave of patent litigation is a "clash driven by company strategies."
"Smart phones combine lots of amazing innovation from both computing and mobile telephony, and technology companies are seeing their patents as a potential source of leverage, ...
Los Angeles, CA (December 7, 2010) Most people feel chills and shivers in response to music that thrills them, but some people feel these chills often and others feel them hardly at all. People who are particularly open to new experiences are most likely to have chills in response to music, according to a study in the current Social Psychological and Personality Science (published by SAGE).
Researchers Emily Nusbaum and Paul Silvia of University of North Carolina at Greensboro asked students about how often they felt chills down their spine, got goose bumps, or felt ...
MADISON — The "A" grades that high schoolers earn aren't just good for making the honor roll — they also make them healthier as adults, too.
Studies have long shown that education is linked to better health, but new research by Pamela Herd, an associate professor of public affairs and sociology at the University of Wisconsin-Madison, shows that higher academic performance in high school plays a critical role in better health throughout life.
"How well you do in school matters," Herd says about the findings, which were published in the December issue of the Journal ...
In many Asian nations, the percentage of the population 65 and older is growing rapidly -- a demographic shift that will pose new social and economic challenges to governments in the region. Preparing for the Challenges of Population Aging in Asia: Strengthening the Scientific Basis of Policy Development, a new report from five national science academies in China, India, Indonesia, Japan, and the U.S., explores the critical issues that rapidly aging populations will raise and identifies research that could help policymakers respond.
The report will be released at 6 p.m. ...
Ground-breaking research from Professor Douglas Kell, published in the journal Archives of Toxicology, has found that the majority of debilitating illnesses are in part caused by poorly-bound iron which causes the production of dangerous toxins that can react with the components of living systems.
These toxins, called hydroxyl radicals, cause degenerative diseases of many kinds in different parts of the body.
In order to protect the body from these dangerous varieties of poorly-bound iron, it is vital to take on nutrients, known as iron chelators, which can bind the iron ...
Los Angeles, CA (December 8, 2010) People who are neurotic often have more difficulty with relationships and marriage. But if neurotic newlyweds have frequent sexual relations, their marital satisfaction is every bit as high as their less neurotic counterparts, according to a study in the current Social Psychological and Personality Science (published by SAGE).
Neuroticism is the tendency to experience negative emotion, and people who are high in it get upset and irritated easily, change their mood often, and worry frequently. People who score high in neuroticism are ...
Watson Land Company, one of Southern California's largest industrial real estate developers, has signed two new leases totaling 105,601 square feet. The transactions, which have a combined value of $3.3 million, mark an increase in South Bay leasing activity corresponding with a rise in port traffic.
"The continued growth of port activity has resulted in many South Bay companies expanding their operations to larger facilities to accommodate the increased volume," said Lance Ryan, vice president of marketing and leasing with Watson Land Company.
In the first transaction, ...
